Microbiologic and Clinical Comparison of Patients Harboring Escherichia coli Blood Isolates with and without Extended-Spectrum β-Lactamases


The clinical and microbiologic characteristics of 34 patients with extended-spectrum β-lactamase (ESBL) positive E. coli isolated from blood were compared to 66 bacteremic patients with ESBL negative E. coli, from January 2007 through December 2009. Of the 21 ESBL positive isolates available for PCR analysis, 13 were positive for CTX-M, 8 for TEM, 4 for SHV β-lactamases, with 6 possessing multiple enzymes. Twenty of 34 (59%) ESBL-positive and 41 of 66 (62%) ESBL-negative blood isolates were considered community-associated. All but one isolate in both groups had MICs of ≤1.0 μg/ml to meropenem. However, when compared to ESBL-negative isolates, ESBL-positive isolates were more frequently resistant to levofloxacin, trimethoprim/sulfamethoxazole and had higher MICs to gentamicin, tobramycin and piperacillin/tazobactam. The use of intravenous and urinary catheters was strongly associated with the isolation of E. coli bloodstream isolates in both groups of patients. Although hospital stay was similar in both groups, appropriate therapy was given in 87% of patients with ESBL positive vs. 98% of patients with ESBL negative isolates and mortality was greater for patients with ESBL positive isolates (26% vs. 17%). Since a large proportion of E. coli blood isolates were ESBL-positive and community-associated, carbapenems should be considered as initial empiric therapy for such infections in our locale.

Share and Cite:

A. Nussbaum, N. Mariano, R. Colon-Urban, R. A. Modeste, S. Zahid, W. Wehbeh, S. Segal-Maurer and C. Urban, "Microbiologic and Clinical Comparison of Patients Harboring Escherichia coli Blood Isolates with and without Extended-Spectrum β-Lactamases," Advances in Infectious Diseases, Vol. 3 No. 1, 2013, pp. 50-54. doi: 10.4236/aid.2013.31006.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] B. A. Rogers, H. E. Sidjabat and D. L. Paterson, “Escherichia coli O25b-ST131: A Pandemic, Multiresistant, Community-Associated Strain,” Journal of Antimicrobial Chemotherapy, Vol. 66, No. 1, 2011, pp. 1-14. doi:10.1093/jac/dkq415
[2] J. D. D. Pitout and K. P. Laupland, “Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: An Emerging Public-Health Concern,” Lancet Infectious Diseases, Vol. 8, No. 1, 2008, pp. 159-166. doi:10.1016/S1473-3099(08)70041-0
[3] J. D. D. Pitout, “Entraintestinal Pathogenic Escherichia coli: A Combination of Virulence with Antibiotic Resistance,” Frontiers in Microbiology, Vol. 3, No. 1, 2012, pp. 1-7. doi:10.3389/fmicb.2012.00009
[4] C. Urban, N. Mariano, P. A. Bradford, M. Tuckman, S. Segal-Maurer, W. Wehbeh, L. Grenner, R. Colon-Urban, B. Johnston, J. R. Johnson and J. J. Rahal, “Identification of CTX-M β-Lactamases in Escherichia coli From Hospitalized Patients and Residents of Long-Term Care Facilities,” Diagnostic Microbiology and Infectious Disease, Vol. 66, No. 4, 2010, pp. 402-406. doi:10.1016/j.diagmicrobio.2009.11.012
[5] H. Tiruvury, N. Mariano, L. Grenner, R. Colon-Urban, M. Erritouni, W. Wehbeh, S. Segal-Maurer, J. J. Rahal, B. Johnston, J. R. Johnson and C. Urban, “Identification of CTX-M β-Lactamases in Escherichia coli From the Community,” Diagnostic Microbiology and Infectious Disease, Vol. 72, No. 3, 2012, pp. 248-252. doi:10.1016/j.diagmicrobio.2011.11.008
[6] K. L. Woods, J. R. Johnson, S. Padkowsky, N. Mariano, R. Colon-Urban, M. Hassanein, W. Wehbeh, B. D. Johnston, C. Clabots, S. Zahid and C. Urban, “Community Associated Escherichia coli Harboring CTX-M-15 β-Lactamases Isolated From Urine Cultures in Pediatric Patients,” Antimicrobial Agents and Chemotherapy, Vol. 56, No. 4, 2012, pp. 2209-2210. doi:10.1128/AAC.00003-12
[7] H. E. Sidjabat, D. L. Paterson, J. M. Adams-Haduch, L. Ewan, A. W. Pasculle, C. A. Muto, G. B. Tian and Y. Doi, “Molecular Epidemiology of CTX-M-producing Escherichia coli at a Tertiary Medical Center in Western Pennsylvania,” Antimicrobial Agents and Chemotherapy, Vol. 53, No. 11, 2009, pp. 4733-4739. doi:10.1128/AAC.00533-09
[8] K. B. Laupland, D. B. Gregson, D. L. Church, T. Ross and J. D. D. Pitout, “Incidence, Risk Factors and Outcomes of Escherichia coli Bloodsteam Infections in a Large Canadian Region,” Clinical Microbiology and Infection Vol. 14, No. 11, 2008, pp. 1041-1047. doi:10.1111/j.1469-0691.2008.02089.x
[9] J. Rodriguez-Bano, E. Picon, J. R. Hernandez, M. Ruiz, C. Pena, M. Almela, B. Almirante, F. Grill, J. Golomina, A. Oliver, J. P. Horcajada, G. Navarro, A. Coloma and A. Pascaul, “Community-Onset Bacteremia Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli: Risk Factors and Prognosis,” Clinical Infectious Diseases, Vol. 50, No. 1, 2010, pp. 40-48. doi:10.1086/649537
[10] S. H. Park, S-M Choi, D-G. Lee, J. Kim, J-H. Choi, S-H Kim, J.-C. Kwon and J.-H. Yoo, “Emergence of Extended-Spectrum β-Lactamase-Producing Escherichia coli as a Cause of Community-Onset Bacteremia in South Korea: Risk Factors and Clinical Outcomes,” Microbial Drug Resistance, Vol. 17, No. 4, 2011, pp. 537-544. doi:10.1089/mdr.2011.0072
[11] D. Marchaim, T. Gottesman, O. Schwartz, M. Korem, Y. Maor, G. Rahav, R. Karplus, T. Lazarovitch, E. Braun, H. Sprecher, T. Lachish, Y. Wiener-Well, D. Alon, M. Chowers, P. Ciobotaro, R. Bardenstein, A. Paz, I. Potas-man, M. Giladi, V. Schechner, M. J. Schwaber, S. Klarfeld-Lidji and Y. Carmeli, “National Multicenter Study of Predictors and Outcomes of Bacteremia upon Hospital Admission Caused by Enterobacteriaceae Producing Extended-Spectrum β-Lactamases,” Antimicrobial Agents and Chemotherapy, Vol. 54, No. 12, 2010, pp. 5099-5104. doi:10.1128/AAC.00565-10
[12] V. P. Chaubey, J. D. D. Pitout, B. Dalton, T. Ross, D. L. Church, D. B. Gregson and K. B. Laupland, “Clinical Outcome of Empiric Antimicrobial Therapy of Bacteremia Due to Extended-Spectrum Beta-Lactamase Producing Escherichia coli and Klebsiella pneumoniae,” BMC Research Notes, Vol. 3, 2010, pp. 116-122. doi:10.1186/1756-0500-3-116
[13] L. Chandramohan and P. A. Revell, “Prevalence and Molecular Characterization of Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in a Pediatric Patient Population,” Antimicrobial Agents and Chemotherapy, Vol. 56, No. 9, 2012, pp. 4765-4770. doi:10.1128/AAC.00666-12
[14] S. Boyer-Mariotte, P. Duboc, S. Bonacorsi, J. F. Lemeland, E. Bingen and D. Pinquier, “CTX-M-15-Producing Escherichia coli in Fatal Neonatal Meningitis: Failure of Empirical Chemotherapy,” Journal of Antimicrobial Chemotherapy, Vol. 62, No. 6, 2008, pp. 1472-1474. doi:10.1093/jac/dkn362
[15] C. Lee, N. Lee, J. Yan, H. Lee, N. Ko, C. Chang, C. Wu, P. Chen, L. Wang and W. Ko, “Extended-Spectrum β-Lactamase-Producing Phenotype Signifies a Poor Prognosis for Patients with Cefpodoxime-Resistant Escherichia coli or Klebsiella pneumoniae Bacteremia,” Journal of Microbiology Immunology and Infection, Vol. 42, No. 4, 2009, pp. 3030-3039.
[16] K. A. Thom, M. L. Schweizer, R. B. Osih, J. C. McGregor, J. P. Furuno, E. N. Perencevich and A. D. Harris, “Impact of Empiric Antimicrobial Therapy on Outcomes in Patients with Escherichia coli and Klebsiella pneumoniae Bacteremia: A Cohort Study,” BMC Infectious Diseases, Vol. 8, 2008, pp.116-125. doi:10.1186/1471-2334-8-116
[17] J. D. D. Pitout. “Extraintestinal Pathogenic Escherichia coli: A Combination of Virulence with Antibiotic Resistance,” Frontiers in Microbiology, Vol. 3, 2012, pp. 1-7. doi:10.3389/fmicb.2012.00009
[18] Y. Doi, Y.S. Park, J. I. Rivera, J. M. Adams-Haduch, A. Hingwe, E. M. Sordillo, J. S. Lewis, W. J. Howard, L. E. Johnson, B. Polsky, J. H. Jorgensen, S. R. Richter, K. A. Shutt and D. L. Paterson, “Community-Associated Extended-Spectrum-β-Lactamase(ESBL)-Producing Escherichia coli Infection in the United States,” Clinical Infectious Diseases, Vol. 56, No. 5, 2013, pp. 641-648. doi:10.1093/cid/cis942

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.